GE HealthCare (GEHC) has inked an agreement with CardioNavix, which is part of the CDL Nuclear Technologies services group, to distribute GEHC's Flyrcado.
Flyrcado (F-18 flurpiridaz) injection is a cardiac imaging agent used with PET myocardial perfusion imaging (MPI). About 6 million MPI procedures are performed each year in the U.S., with about 5% to 10% of these being PET MPI exams, according to GEHC.
CDL offers end-to-end cardiac PET imaging resources to hospitals and outpatient practices throughout the U.S., GEHC said. The distribution agreement will begin in late 2025.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
